Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus

Archives of Medical Science

Volumn 7, Issue 5, 2011, Pages 864-869

  Skrȩtkowicz, Jadwiga ^a   Baranśka, Magłorzata ^a   Kaczorowska, Anna ^a   Rychlik Sych, Mariola ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Genetic polymorphism; Oxidation; Systemic lupus erythematosus

Indexed keywords

CYTOCHROME P450 2D6; DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA EXTRACTION; ENZYME METABOLISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLAND; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; WILD TYPE;

EID: 81555203003     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.25563     Document Type: Article

References (30)

1. Sanchez E, Sabio JM, Callejas J, et al. Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Medical Genetics 2006; 7: 48-55.
2. Nambiar MP, Juang YT, Krishanan S, Tsokos GC. Dissecting the molecular mechanisms of TCR ζ chain downregulation and T cell signaling abnormalities in human systemic lupus erythematosus. Int Rev Immunol 2004; 23: 245-63. (Pubitemid 38812229)
3. Von Schmiedeberg S, Fritsche E, Ronnau AC, et al. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic lupus erythematosus. Adv Exp Med Biol 1999; 45: 145-52.
4. Skrȩtkowicz J, Skrȩtkowicz-Szarmach K, Rychlik-Sych M. Genetic factors in pathogenesis of lupus erythematosus. Reumatologia 2004; 42: 267-72.
5. Linsey A, Criswell MD. The genetic contribution to systemus lupus erythematosus. Bull NYU Hosp Jt Dis 2008; 66: 176-83.
6. Yu A, Kneller BM, Rettie AE, Haining RL. Expression, putification, biochemical characterization, and compa - rative function of human cytochrome P450 2 D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 2002; 303: 1291-300. (Pubitemid 35424416)
7. Perera FP, Deliang T, Brandt-Rauf P, et al. Lack of Associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in nested case-CONTROL study of lung cancer within the physicians' health study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1417-9. (Pubitemid 44125305)
8. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006; 25: 1679-91.
9. Ingelman-Sunberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharma - cogenom J 2005; 5: 6-13.
10. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics. Useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-47.
11. Ken-Ichi F. Cytochrome P450 and anticancer drugs. Curr Drug Metabol 2006; 7: 23-37.
12. Van Schaik RHN. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005; 23: 513-22. (Pubitemid 43162470)
13. Goła̧b-Janowska M, Honczarenko K, Gawrońska-Szklarz B, Potemkowski A. CYP2D6 gene polymorphism as a probable risk factor for Alzhaimer's disease and Parkinson's disease with dementia. Neurol Neurochir Pol 2007; 41: 113-21. (Pubitemid 46745847)
14. Kortunay S, Bozkurt A, Bathum L, et al. CYP2D6 poly - morphism in systemic lupus erythematosus patients. Eur J Clin Pharmacol 1999; 55: 21-5. (Pubitemid 29144095)
15. Sabbagh N, Marez D, Queyrel V, et al. Genetic analysis of cytochrome P450 CYP2D6 polymorphism in patients with systemic lupus erythematosus. Pharmacogenetics 1998; 8: 191-4. (Pubitemid 28282875)
16. Hochberg MG. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40; 1725-8.
17. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-7.
18. Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P-450 activity in human and rat. Pharmacol Reports 2008; 60: 789-97.
19. Hosseini M, Houshmand M, Ebrahimi A. Breast cancer risk only was not assaciated with CYP17/A2 allele but also was related to A1 allele. Ach Med Sci 2009; 5: 103-6.
20. Ledesma MC, Agundez JAG. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin Chem 2005; 51: 939-43. (Pubitemid 40740872)
21. Sobti RC, Onsory K, Al-Badran AI, et al. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 2006; 5: 287-94. (Pubitemid 43830442)
22. Sobti RC, Al-Badran AI, Sharma S, Sharma SK, Krishan A, Mohad H. Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India. Cancer Genet Cytogenet 2005; 156: 68-73. (Pubitemid 39601062)
23. Łapiński Ł, Agundez JAG, Wiela-Hojeńska A, et al. CYP2D6 gene amplification and the risk of acute myeloblastic leukemia. Pharmacol Rep 2007; 59 suppl. 1: 167-72.
24. Niewiński P, Orzechowska-Józwenko K, Hurkacz M, et al. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. Eur J Pharmacol 2002; 58: 533-5. (Pubitemid 35439153)
25. Yamada H, Dahl M, Viitanen M. No association between familial Alzheimer disease and cytochrome P450 poly - morphism. Alzheimer Dis Assoc Disord 1998; 12: 204-7. (Pubitemid 29154990)
26. Woo S, Kim JW, Seo HG. Cyp2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Psych Clin Neurosci 2001; 55: 373-7. (Pubitemid 32776819)
27. Rychlik-Sych M, Skrȩtkowicz J, Gawrońska-Szklarz B, Górnik W, Sysa-Jȩdrzejowska A, Skrȩtkowicz-Szarmach K. Acetylation genotype and phenotype in patients with systemic lupus erythemotosus. Pharmacol Rep 2006; 58: 22-9.
28. Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol 2001; 41: 815-50. (Pubitemid 32385908)
29. Fukuda T, Maune H, Ikenaga Y, Naohara M, Fukuda K, Azuma J. Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele. Drug Met Pharmacokinet 2005; 20: 345-50.
30. Yen JH, Chen CJ, Tsai WC, et al. Cytochrome P450 and manganese superoxide dismutase genes polymorphisms in lupus systemic erythematosus. Immunol Lett 2003; 90: 19-24.